CRISPR/cas13-medIated RNA TarGeting THerapy for the Treatment of Neovascular Age-related Macular Degeneration Investigator-initiated Trial (SIGHT-I)

NCT06031727 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular Age-related Macular Degeneration(nAMD)

Interventions

GENETIC: HG202

Sponsor

HuidaGene Therapeutics Co., Ltd.

Collaborators

[object Object]
[object Object]